132 search results for “exposure therapy” in the Staff website
-
Danielle Oprel
Faculteit der Sociale Wetenschappen
d.a.c.oprel@fsw.leidenuniv.nl | +31 71 527 2727
-
Rianne de Kleine
Faculteit der Sociale Wetenschappen
r.a.de.kleine@fsw.leidenuniv.nl | +31 71 527 5435
-
Marike Kooistra
Faculteit der Sociale Wetenschappen
m.j.kooistra@fsw.leidenuniv.nl | +31 71 527 1726
-
Mona Shahab
Faculteit der Sociale Wetenschappen
m.k.shahab@fsw.leidenuniv.nl | +31 71 527 2727
-
Webinar Transfusion Medicine and Cellular and Tissue Therapies
Study information
-
Erica Bohnen
Faculteit der Sociale Wetenschappen
e.a.h.bohnen@fsw.leidenuniv.nl | +31 71 527 3381
-
Douwe Atsma
Faculteit Geneeskunde
d.e.atsma@lumc.nl | +31 70 526 2020
-
Jessy Terpstra
Faculteit der Sociale Wetenschappen
j.a.terpstra@fsw.leidenuniv.nl | +31 71 527 2727
-
Review paper on the potential impact drug-metabolizing enzymes on brain exposure
PhD candidate Mengxu Zhang (Division of Systems Pharmacology and Pharmacy) published a comprehensive and important review on “The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure” in Drug Metabolism Reviews.
-
Developing new therapies to fight muscle disease
Biophysicist Alireza Mashaghi and his collaborators are taking up the fight against muscular dystrophy: genetic disorders that cause muscle weakness. They want to inhibit the clumping of proteins that results in toxic aggregates. For this, the team receives 550,000 euros from Health Holland. The team…
-
Cevdet Acarsoy
Faculteit der Sociale Wetenschappen
c.acarsoy@fsw.leidenuniv.nl | +31 71 527 2727
-
Rethinking antibiotic therapy of urinary tract infections
Suruchi Nepal, postdoc in the group of Coen van Hasselt at LACDR, was awarded an NWO XS project which aims to study the response to antibiotic treatment during a urinary tract infection (UTI). This knowledge will be used to determine how treatments of UTIs with antibiotics can be further improved.
-
LUMC signs international agreement on developing Advanced Therapy Medicinal Products
Skåne University Hospital, Lund University and Leiden University Medical Center will work together to expand their research, teaching and development relating to Advanced Therapy Medicinal Products. That is the essence of a Memorandum of Understanding signed at SciLifeLab near Stockholm on Wednesday…
-
Special nanoparticles for cancer therapy! Will you help?
Developing a better treatment for patients with head and neck cancer, that is what Binanox, The 2022 iGEM Leiden team, want to achieve. They hope to raise at least 10,000 euros for this cause. Support their crowdfunding campaign today.
-
patient in the Netherlands successfully treated with stem cell gene therapy
Researchers from the Leiden University Medical Center (LUMC) have successfully used stem cell gene therapy to treat a baby with the severe congenital immune disorder SCID. An important milestone: it is the first time stem cell gene therapy of Dutch origin has been administered to a patient, and also…
-
Femke Stad
Faculteit der Sociale Wetenschappen
f.e.stad@fsw.leidenuniv.nl | +31 71 527 6790
-
Katja Cardol
Faculteit der Sociale Wetenschappen
c.k.cardol@fsw.leidenuniv.nl | +31 71 527 5697
-
X-ray mirrors: useful in space, but also for radiation therapy
A special type of mirror to reflect X-rays has more possible applications than space research. Targeted radiation therapy for cancer, for example. Next to his full-time job, physicist David Girou mapped out the possibilities. He will receive his PhD on 14 June.
-
Chris Hoeboer
Faculteit der Sociale Wetenschappen
c.m.hoeboer@fsw.leidenuniv.nl | +31 71 527 2727
-
Bianca Boyer
Faculteit der Sociale Wetenschappen
b.e.boyer@fsw.leidenuniv.nl | +31 71 527 2727
-
Nina Komrij
Faculteit der Sociale Wetenschappen
n.l.komrij@fsw.leidenuniv.nl | +31 71 527 5378
-
Judith Bovée
Faculteit Geneeskunde
j.v.m.g.bovee@lumc.nl | +31 71 526 9111
-
David Heyne
Faculteit der Sociale Wetenschappen
d.heyne@fsw.leidenuniv.nl | +31 71 527 2727
-
Veronica Janssen
Faculteit der Sociale Wetenschappen
v.r.janssen@fsw.leidenuniv.nl | +31 71 527 2727
-
Biological agents
Biological agents are micro-organisms such as bacteria, parasites, moulds, viruses and their waste products. This category also includes genetically modified variants (GMOs). These agents may form a risk for your health, which is why we apply a number of legal and other guidelines to prevent people…
-
Philip Spinhoven
Faculteit der Sociale Wetenschappen
spinhoven@fsw.leidenuniv.nl | +31 71 527 2727
-
Willem van der Does
Faculteit der Sociale Wetenschappen
vanderdoes@fsw.leidenuniv.nl | +31 71 527 8482
-
Oana Georgiana Rus-Oswald
Faculteit der Sociale Wetenschappen
o.g.rus@fsw.leidenuniv.nl | +31 71 527 2727
-
Lioe-Fee de Geus-Oei
Faculteit Geneeskunde
l.f.de_geus-oei@lumc.nl | +31 71 526 9111
-
Sylvestre Bonnet
Science
bonnet@chem.leidenuniv.nl | +31 71 527 4260
-
Dynamics and regulation of the oxidative stress response upon chemical exposure
PhD defence
-
Is a cancer pill a matter of time?
A cancer pill, preferably without severe side effects, is something we’d all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves are contributing to new cancer treatments.
-
Incidents and dangerous situations
Together we create a healthy and safe working environment. Should an incident, dangerous situation or needle-stick injury nevertheless occur, please report it immediately. Such incidents are far more frequent than serious accidents. By reporting them we can make sure that they do not lead to serious…
-
Proof of Concept grants for four Leiden researchers
Four Leiden researchers have been awarded Proof of Concept grants by the ERC. These grants, each worth 150,000 euros, help researchers translate the findings of previous ERC projects into innovative practical applications.
- Events
-
Health insurance
If you wish, you can take part in the collective health insurance scheme offered by Leiden University and Zorg en Zekerheid. This scheme offers a collective discount, for you and your family.
-
A safe work environment
Regardless of whether you work at a desk or in a lab, all workplaces have their risks. As your employer, the University aims to create a healthy workplace and to limit possible health risks. Here you will find the main risks and measures that we take to reduce them.
-
A safe workplace
Regardless of whether you work at a desk or in a lab, all workplaces have their risks. As your employer, the University aims to create a healthy workplace and to limit possible health risks. Here you will find the main risks and measures that we take to reduce them.
-
Leiden researchers join forces against tuberculosis
About one and a half million people worldwide die each year from tuberculosis. For thirty years, therapy with antibiotics has been the same, while it takes far too long and can lead to resistant pathogens. Leiden researchers from four institutes are now joining forces to develop more effective and efficient…
-
Four Leiden Scientists: 'Environmental risks of new pesticides with nanoparticles insufficiently examined'
The environmental risks of new pesticides containing nanoparticles are inadequately researched, according to four Leiden scientists in the scientific journal Environmental Science & Technology. They call for an examination of the long-term and environmental effects of pesticides containing nanoparti…
-
Leiden University Academy Week
Study information
-
Grant Elise Mathilde Fund & LUF: Using virus to kill bacteria: design of innovative phage-antibiotic combination treatments to combat antimicrobial
Phage therapy is a novel yet unmatured therapeutic approach in the face of the crisis of antimicrobial resistance (AMR). Dr. Tingjie Guo received a grant from the Elise Mathilde Fund and the LUF to develop innovative phage-antibiotic combination treatment strategy for combating AMR.
-
Medical Delta professor Marco van Vulpen: ‘I advocate the introduction of the share factor’
Proton therapy is a new way of treating cancer in which radiation doses are delivered more precisely. This results in less damage to surrounding tissue and fewer side effects. Professor Marco van Vulpen is medical director of HollandPTC in Delft, where the social value of this therapy is studied. Van…
-
New insights into mycobacterial infections with NWO grant
Why are mycobacteria such successful pathogens? And are there defence mechanisms in the body that help reduce an infection? To find out, Annemarie Meijer has been awarded the NWO Open Competition ENW-XL grant. She will not explore this quest alone. Five other leading Dutch research groups are participating…
-
Oncode Accelerator launched: patients at the centre of innovative cancer drug development
Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process.
-
Nature Communications paper on therapeutic melanoma inhibition by local micelle-mediated cyclic nucleotide repression
Cancer immunotherapy represents a significant breakthrough in cancer treatment. However, tumors have numerous mechanisms by which they evade destruction by the immune system. It is therefore necessary to decipher and reverse these mechanisms in order to improve immunotherapies.
-
funders
Many national and international research funders can provide financing for your research project.
-
Sibel Bahtiri is one of the new Faces of Science: ‘I want to show how we’re finding alternatives to animal testing’
PhD candidate Sibel Bahtiri is one of the new Faces of Science. In videos and blogs, she will show what life is like as a young researcher.
-
Polypeptide Therapeutic Solutions and Universiteit Leiden Announce Collaboration to Develop Advanced Polyaminoacid Drug Delivery Systems
Polypeptide Therapeutic Solutions (PTS), a leader in the design, development and custom manufacturing of polyamino-acid based delivery systems for therapeutic drugs and the Leiden Academic Centre for Drug Research (LACDR) today announced a research collaboration to develop advanced drug delivery systems…
-
300 million euros for new international stem cell consortium
The Leiden University Medical Center (LUMC), the Danstem Institute from the University of Copenhagen and the Murdoch Children’s Research Institute in Melbourne have received 300m euros from the Novo Nordisk foundation. The aim of this new international consortium is to bring stem-cell based therapies…